Rob de Ree, CEO, Dezima: Developing innovative drugs in the field of dyslipidemia




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Rob de Ree, CEO, Dezima: Developing innovative drugs in the field of dyslipidemia
Released on: February 28, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    in this interview, filmed at BIO Europe 2013 in Vienna, Paul Larsmon speaks to Rob de Ree, CEO of Dezima Pharma.
  • Summary
  • Transcript
  • Participants
  • Company
in this interview, filmed at BIO Europe 2013 in Vienna, Paul Larsmon speaks to Rob de Ree, CEO of Dezima Pharma.
Rin this interview, filmed at BIO Europe 2013 in Vienna, Paul Larsmon speaks to Rob de Ree, CEO of Dezima Pharma.
Rob de Ree
Dezima
Dezima Pharma
Dezima Pharma develops novel drugs to treat dyslipidemia Dyslipidemia is a major modifiable risk for cardiovascular disease. Dezima's objective is to develop novel compounds from pre-clinical development to meaningful proof of concept (PoC) in patients. Following PoC, Dezima will seek strategic partners to further development in the larger cardiovascular indications, and/or continue in-house development of its compounds in smaller, orphan-type indications. Netherlands-based Dezima Pharma was founded in 2012 by Forbion Capital Partner and BioGeneration Ventures.